Skip to content

Ozempic diarrhea: what the GLP-1 labels report

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

The short answer

Ozempic diarrhea is on the injection label: in two trials in adults with type 2 diabetes, 8.5% of patients on 0.5 mg and 8.8% on 1 mg reported it, against 1.9% on placebo. All eight GLP-1 labels we track list diarrhea in their tables. Zepbound's reports 19% to 23%, against 8% on placebo. If you can't drink enough to keep up, contact your prescriber.

Key takeaways

  • All eight GLP-1 labels list diarrhea in their tables of common reactions.
  • Contact your prescriber if diarrhea is frequent or lasting, or if you can't drink enough to keep up.
  • The labels link dehydration from diarrhea, nausea or vomiting to acute kidney injury.
  • Persistent or severe abdominal pain needs prompt medical attention, because the labels list it as a sign of pancreatitis.
  • Don't hold or change a dose on your own. Ask your prescriber.

How often it was reported in the label's trials

Zepbound: Table 1: Adverse Reactions (≥2% and Greater than Placebo) in ZEPBOUND-Treated Adults with Obesity or Overweight in Weight Reduction and Long-term Maintenance Trials (Study 1 and Study 2) · Pool of two randomized, double-blind, placebo-controlled weight reduction trials (Study 1 and Study 2) that included 2,519 adults with obesity or overweight, with or without type 2 diabetes, treated with Zepbound for up to 72 weeks plus a 4-week off-drug follow-up period.
ReactionPlacebon=9585 mgn=63010 mgn=94815 mgn=941
Diarrhea8%19%21%23%

FDA label: Zepbound, Revised: 8/2026 (DailyMed version 40)

Mounjaro: Table 1: Adverse Reactions in Pool of Placebo-Controlled Trials Reported in ≥5% of MOUNJARO-treated Adult Patients with Type 2 Diabetes Mellitus · Pool of two placebo-controlled trials in adults with type 2 diabetes (SURPASS-1 monotherapy and SURPASS-5 added to basal insulin with or without metformin); 718 patients exposed to Mounjaro for a mean of 36.6 weeks. Hypoglycemia is not included.
ReactionPlacebon=2355 mgn=23710 mgn=24015 mgn=241
Diarrhea9%12%13%17%

FDA label: Mounjaro, Revised: 8/2026 (DailyMed version 40)

Wegovy: Table 3. Adverse Reactions (≥2% and Greater Than Placebo) in WEGOVY 2.4 mg Injection-treated Adults with Obesity or Overweight for Weight Reduction · Adults with obesity or overweight in 3 randomized, double-blind, placebo-controlled trials, treated with Wegovy 2.4 mg injection for up to 68 weeks plus a 7-week off-drug follow-up. The label shows '<1' for placebo eructation. The hypoglycemia row is for patients with type 2 diabetes not on insulin (Study 3: Wegovy N=403, placebo N=402). Abdominal pain, fatigue, gastritis and dysesthesia are grouped terms.
ReactionPlacebon=1261Wegovy injection 2.4 mg once weeklyn=2116
Diarrhea16%30%
Wegovy: Table 5. Adverse Reactions (≥3% and Greater than Placebo) in WEGOVY 2.4 mg Injection-treated Pediatric Patients Aged 12 Years and Older with Obesity for Weight Reduction · Pediatric patients aged 12 years and older with obesity in a 68-week, double-blind, randomized, placebo-controlled trial of Wegovy 2.4 mg injection.
ReactionPlacebon=67Wegovy injection 2.4 mg once weeklyn=133
Diarrhea19%22%

FDA label: Wegovy, Revised: 6/2026 (DailyMed version 19)

Ozempic: Table 1. Adverse Reactions in Placebo-Controlled Trials Reported in ≥5% of OZEMPIC-Treated Patients with Type 2 Diabetes Mellitus · Adults with type 2 diabetes in 2 placebo-controlled trials (1 monotherapy trial and 1 trial in combination with basal insulin); mean duration of exposure to Ozempic was 32.9 weeks. The table excludes hypoglycemia.
ReactionPlacebon=262Ozempic 0.5 mgn=260Ozempic 1 mgn=261
Diarrhea1.9%8.5%8.8%

FDA label: Ozempic, Revised: 5/2026 (DailyMed version 20)

Foundayo: Table 1: Adverse Reactions Reported in ≥5% of FOUNDAYO-treated Adult Patients with Obesity or Overweight (With or Without Type 2 Diabetes) in Pool of Placebo-Controlled Trials (Trials 1 and 2) · Pool of two randomized, double-blind, placebo-controlled weight management trials (Trials 1 and 2) that included 3155 adults with obesity or overweight, with or without type 2 diabetes, treated with Foundayo once daily for up to 72 weeks plus a 2-week off-drug follow-up period.
ReactionPlacebon=15765.5 mgn=10519 mgn=105517.2 mgn=1049
Diarrhea11%21%23%25%

FDA label: Foundayo, Revised: 7/2026 (DailyMed version 10)

Rybelsus: Table 2. Adverse Reactions in Placebo-Controlled Trials Reported in ≥5% of Semaglutide Tablets-Treated Patients with Type 2 Diabetes Mellitus · Adults with type 2 diabetes in 2 placebo-controlled trials of semaglutide tablets (Rybelsus); mean duration of exposure was 41.8 weeks. The table excludes hypoglycemia.
ReactionPlacebon=362Semaglutide tablets 7 mgn=356Semaglutide tablets 14 mgn=356
Diarrhea4%9%10%

FDA label: Rybelsus, Revised: 1/2026 (DailyMed version 14)

Saxenda: Table 2. Adverse Reactions Occurring in ≥2% of SAXENDA-treated Adult Patients and More Frequently than Placebo · Adults with overweight or obesity in 5 double-blind, placebo-controlled trials, treated for up to 56 weeks (3 trials), 52 weeks (1 trial) and 32 weeks (1 trial). The hypoglycemia row is for patients with type 2 diabetes not on insulin (Study 2: Saxenda N=423, placebo N=212), defined as blood glucose below 54 mg/dL with or without symptoms.
ReactionPlacebon=1941Saxendan=3384
Diarrhea9.9%20.9%
Saxenda: Table 3. Adverse Reactions Occurring in ≥3% of SAXENDA-treated Pediatric Patients and More Frequently than Placebo in a 56 Week Clinical Trial · Pediatric patients aged 12 years and older with obesity, without type 2 diabetes, in a 56-week placebo-controlled trial. The hypoglycemia row is defined as blood glucose below 70 mg/dL with symptoms.
ReactionPlacebon=126Saxendan=125
Diarrhea14.3%22.4%

FDA label: Saxenda, Revised: 6/2026 (DailyMed version 22)

Trulicity: Table 1: Adverse Reactions in Pool of Placebo-Controlled Trials That Occurred in ≥5% of TRULICITY-Treated Adult Patients with Type 2 Diabetes Mellitus · Pool of placebo-controlled trials that included 1,670 adults with type 2 diabetes exposed to Trulicity 0.75 mg or 1.5 mg, with a mean duration of exposure of 23.8 weeks. Hypoglycemia is excluded.
ReactionPlacebon=5680.75 mgn=8361.5 mgn=834
Diarrhea6.7%8.9%12.6%
Trulicity: Table 2: Adverse Reactions That Occurred in ≥5% of TRULICITY-treated Adult Patients with Type 2 Diabetes Mellitus in a Clinical Trial through 36 Weeks · Clinical trial of 1842 adults with type 2 diabetes treated with Trulicity 1.5 mg, 3 mg, or 4.5 mg once weekly as add-on to metformin, through 36 weeks (no placebo arm).
Reaction1.5 mgn=6123 mgn=6164.5 mgn=614
Diarrhea7%11.4%10.7%

FDA label: Trulicity, Revised: 3/2026 (DailyMed version 62)

Each medicine's figures come from its own trials, which differ in dose, length and who took part. They are not a head-to-head comparison.

If you have diarrhea on a GLP-1 medicine, the thing to watch is dehydration. Contact your prescriber if it’s frequent or lasting, if you can’t drink enough to keep up, or if it arrives together with vomiting. Persistent or severe abdominal pain needs prompt medical attention.

Diarrhea sits in the table of common reactions on every GLP-1 label we track. The label tables on this page give each figure, and the notes below put them in context.

What do the labels report for diarrhea?

Each figure is the share of trial patients who reported diarrhea, next to the placebo group from the same trials. A placebo group gets an inactive treatment instead of the medicine.

  • Mounjaro (adults with type 2 diabetes, two pooled placebo-controlled trials): 12% at 5 mg, 13% at 10 mg and 17% at 15 mg, with 9% on placebo.
  • Zepbound (adults with obesity or overweight, two pooled trials of up to 72 weeks): 19% at 5 mg, 21% at 10 mg and 23% at 15 mg, with 8% on placebo.
  • Foundayo (adults with obesity or overweight, two pooled trials): 21% at 5.5 mg, 23% at 9 mg and 25% at 17.2 mg, with 11% on placebo.
  • Wegovy 2.4 mg injection (adults, three weight reduction trials): 30%, with 16% on placebo.
  • Saxenda (adults, five trials): 20.9%, with 9.9% on placebo.
  • Ozempic injection (adults with type 2 diabetes, two trials): 8.5% at 0.5 mg and 8.8% at 1 mg, with 1.9% on placebo.
  • Rybelsus (adults with type 2 diabetes, two trials; the label also covers Ozempic tablets): 9% at 7 mg and 10% at 14 mg, with 4% on placebo.
  • Trulicity (adults with type 2 diabetes, pooled trials): 8.9% at 0.75 mg and 12.6% at 1.5 mg, with 6.7% on placebo. In its higher-dose trial, which had no placebo arm: 7.0% at 1.5 mg, 11.4% at 3 mg and 10.7% at 4.5 mg.

In adolescents aged 12 and older with obesity, the Wegovy label reports 22% on 2.4 mg and 19% on placebo, and the Saxenda label reports 22.4% and 14.3%.

One table leaves diarrhea out. Wegovy’s table for the 7.2 mg dose includes only reactions that were more frequent on 7.2 mg than on both 2.4 mg and placebo, and diarrhea isn’t listed there. That tells you about the table’s cutoff. It doesn’t show that diarrhea can’t happen at the higher dose.

Why the placebo column matters here

Diarrhea is common in the general population, and the placebo groups show it. In the Wegovy adolescent trial, 19% of the placebo group reported diarrhea, three points below the treated group. In the Mounjaro pool, the 5 mg group was three points above placebo. In other trials the gap was wider.

The trials differ in who took part, how long they ran and how reactions were counted. So you can’t use these gaps to rank the medicines. What each row does tell you is how that medicine did against its own placebo group.

When does diarrhea occur?

Mostly during dose increases, which the labels call dose escalation. The Zepbound label says the majority of nausea, vomiting and diarrhea events occurred during dose escalation and decreased over time. Foundayo’s label says the incidence of the same three reactions was higher during the dosage escalation period and decreased over time. The Ozempic and Rybelsus labels say the majority of reports occurred during dose escalation, and Wegovy’s says gastrointestinal (stomach and bowel) reactions were most frequently reported during dosage escalation.

The warning behind it: dehydration and the kidneys

All eight labels carry a warning headed “Acute Kidney Injury Due to Volume Depletion.” Volume depletion means losing too much fluid. Mounjaro’s reads: “There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with GLP-1 receptor agonists, or MOUNJARO. The majority of the reported events occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration such as nausea, vomiting, or diarrhea.”

In plain words, postmarketing reports are reports made after approval, and hemodialysis is a treatment in which a machine filters the blood.

Two labels report trial figures for this warning. In Zepbound’s pooled trials, acute kidney injury was reported in 0.5% of treated patients and 0.2% on placebo. In Foundayo’s, 0.2% and 0.05%.

The labels also warn that gastrointestinal reactions are sometimes severe. Severe reactions of any gastrointestinal type were reported by 4.1% of adults on Wegovy injection against 0.9% on placebo, and by 4.8% on Saxenda against 1.4% on placebo.

When to contact your prescriber

The Wegovy and Rybelsus labels tell prescribers to monitor kidney function in patients who report reactions that could lead to volume depletion, especially while the dose is being started and raised. That monitoring starts with you reporting it. Contact your prescriber if diarrhea is frequent or lasting, if you can’t drink enough to keep up, or if it arrives together with vomiting. Persistent or severe abdominal pain needs prompt medical attention, because the labels list it as a sign of pancreatitis, an inflammation of the pancreas.

Don’t hold or change a dose on your own. Ask first. For the opposite problem, see constipation, and for all reactions, the GLP-1 side effects guide or the Mounjaro guide.

Frequently asked questions

Does Ozempic cause diarrhea?

The Ozempic injection label lists diarrhea in its table of common side effects. In two trials in adults with type 2 diabetes, 8.5% of patients on 0.5 mg and 8.8% on 1 mg reported it, compared with 1.9% on placebo. The label says most reports of nausea, vomiting and diarrhea came during dose escalation, the weeks when the dose is being raised.

Does Mounjaro cause diarrhea?

The Mounjaro label lists diarrhea in its table of common side effects. In the pool of two placebo-controlled trials in adults with type 2 diabetes, 12% of patients on 5 mg, 13% on 10 mg and 17% on 15 mg reported it. So did 9% of patients on placebo, which means part of what was reported would have occurred without the medicine.

Does Zepbound cause diarrhea?

In Zepbound's two pooled weight reduction trials in adults with obesity or overweight, 19% of patients on 5 mg, 21% on 10 mg and 23% on 15 mg reported diarrhea, compared with 8% on placebo. The label says most nausea, vomiting and diarrhea events occurred during dose escalation (while the dose was being raised) and decreased over time.

Is diarrhea on a GLP-1 dangerous?

The labels treat the dehydration it can cause as the concern. Each one warns of acute kidney injury due to volume depletion (losing too much fluid), and the Zepbound, Mounjaro, Foundayo and Trulicity labels say most reported cases were in patients whose nausea, vomiting or diarrhea led to dehydration. If you can't keep up by drinking, contact your prescriber.

Do people stop treatment because of diarrhea?

A small share do. In the adult Wegovy 2.4 mg trials, diarrhea led 0.7% of patients to stop for good, against 0.1% on placebo. In the adult Saxenda trials it was 1.4%, against 0% on placebo. The other labels report stopping for stomach and bowel reactions as a group, without a separate figure for diarrhea.

Sources (8)

  1. 1.
  2. 2.
  3. 3.
  4. 4.
  5. 5.
  6. 6.
  7. 7.
  8. 8.